28 June 2024
N4 Pharma plc
("N4 Pharma" or the "Company")
Total Voting Rights
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 394,780,349 ordinary shares of 0.4 pence each ("Ordinary Shares").
The total issued share capital of the Company consists of 394,780,349 Ordinary Shares. The Company does not hold any Ordinary Shares in Treasury. Therefore, the total current voting rights in the Company is 394,780,349 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
|
N4 Pharma plc |
|
|
Nigel Theobald, CEO |
Via IFC Advisory |
|
Luke Cairns, Executive Director |
|
|
|
|
|
SP Angel Corporate Finance LLP |
Tel: +44(0)20 3470 0470 |
|
Nominated Adviser and Joint Broker |
|
|
Matthew Johnson/Caroline Rowe/ Kasia Brzozowska (Corporate Finance) |
|
|
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) |
|
|
|
|
|
Turner Pope Investments (TPI) Limited |
Tel: +44(0)20 3657 0050 |
|
Joint Broker |
|
|
Andy Thacker James Pope |
|
|
|
|
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.
For further information on the Company visit www.n4pharma.com or sign up at investors.n4pharma.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
